Company intelligence / Profile preview

GiMer Medical

Ownership: Private
Development stage: Commercial

Overview

GiMer Medical has developed and clinically validated implantable and wearable neuromodulation devices for chronic pain management. Its spinal cord stimulation system received FDA IDE approval in August 2022, with multiple clinical trials completed demonstrating efficacy in chronic back pain and carpal tunnel syndrome. The company’s wearable StimOn device has also been cleared to market in the US.

Therapeutic areas: OncologyRheumatologyNeurology
Modalities: DeviceElectrical stimulation systemNeuromodulation device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

StimOn

Commercial

Indications: Pain management

Partnerships

Medtronic (backed by Medtronic as a strategic partner/investor)

Beyond the preview

Go deeper on GiMer Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GiMer Medical.

Explore the full profile